Catalyst
Slingshot members are tracking this event:
FDA Approves Neurocrine's (NBIX) INGREZZA (valbenazine) New Drug Application (NDA) in Tardive Dyskinesia
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NBIX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 11, 2017
Occurred Source:
http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=2261466
Related Projects
- Discussing the Market Potential of Neurocrine's (NBIX) Ingrezza for Tardive Dyskinesia After April 11th PDUFA NBIX, TEVA, VRX Executed On: Apr 19, 2017 at 01:30 PM EDT
Related Keywords
Ingrezza, Pdufa, Fda, New Drug Application, Tardive Dyskinesia
